


Toronto Spondyloarthritis and Psoriatic Arthritis Symposium

Second edition



Friday, 13 November 2026
10:00 am – 4:30 pm ET

BMO Education & Conference Centre
60 Leonard Avenue, Toronto, ON M5T 2R1
In person and virtually

Breakfast from 9:15 am.

Welcome

Dear colleagues,

It is our pleasure to welcome you to the second Toronto Spondyloarthritis and Psoriatic Arthritis Symposium. Following last year's inaugural meeting, we are continuing this educational forum focused on the diagnosis and management of spondyloarthritis and psoriatic arthritis.

The programme brings together rheumatologists, trainees and allied healthcare professionals for updates relevant to clinical practice. It combines expert presentations with a hands-on imaging workshop and discussion of challenging cases submitted by participants.

We hope the meeting will provide useful clinical insights and an opportunity for discussion with colleagues. We look forward to seeing you in Toronto or online.

Nigil Haroon Vinod Chandran Denis Poddubnyy

At a glance

Audience

Rheumatologists, residents, fellows and allied healthcare professionals interested in SpA and PsA.

Format

In-person and virtual attendance. The practical imaging workshop is designed for active participation.

Imaging workshop

In-person participants are encouraged to bring a laptop or tablet to view cases. A podium computer will be available for presentations.

Participant cases

Cases may be submitted through the symposium case submission area. Upload only de-identified material and confirm the necessary permissions for discussion.

Programme

Time	Session	Faculty
09:15–10:00	Breakfast	
10:00–10:05	Welcome and introduction	Denis Poddubnyy
10:05–10:35	Axial spondyloarthritis: what is new in 2026? ACR update	Nigil Haroon
10:35–10:45	Questions and discussion	
10:45–11:15	Imaging for the diagnosis of axial spondyloarthritis and psoriatic arthritis	Kay-Geert Hermann
11:15–11:30	Questions and discussion	
11:30–11:45	Break	
11:45–13:15	Interactive workshop: Imaging of the sacroiliac joints and spine	Denis Poddubnyy
13:15–14:00	Lunch	
14:00–14:30	Psoriatic arthritis: what is new in 2026? ACR update	Vinod Chandran
14:30–14:45	Questions and discussion	
14:45–16:15	Case discussion: Diagnostic and management challenges in SpA	Nigil Haroon, Vinod Chandran and Denis Poddubnyy
16:15–16:30	Wrap-up and adjourn	All faculty

Programme subject to minor adjustments. ACR update sessions will cover findings available by the meeting.

Learning objectives

By the end of the symposium, participants will be able to:

1. Summarize recent clinical and research updates in axSpA and PsA, including selected findings presented at ACR 2026.
2. Interpret sacroiliac joint and spinal imaging findings and distinguish inflammatory lesions from common mimics.
3. Apply a practical approach to viewing MRI studies and assessing suspected axial spondyloarthritis.
4. Discuss diagnostic and management options for challenging SpA and PsA cases in clinical practice.

Session objectives

Axial spondyloarthritis update

Summarize recent advances in classification, diagnosis and treatment of axSpA, including selected ACR 2026 findings.

Diagnostic imaging

Recognize imaging features relevant to axSpA and PsA and distinguish inflammatory findings from mechanical or degenerative changes.

Sacroiliac joint and spine imaging workshop

Navigate images, identify key MRI sequences, adjust image display and recognize active and structural lesions.

Psoriatic arthritis update

Discuss recent advances in classification and management of PsA, including selected ACR 2026 findings.

Case discussion

Evaluate diagnostic uncertainty and therapeutic choices in cases submitted by participants.

CanMEDS roles

Medical Expert · Collaborator · Scholar · Professional

Faculty

Denis Poddubnyy, MD, PhD

Professor of Medicine and Division Director, Division of Rheumatology, Department of Medicine, University of Toronto; Clinician Investigator and Staff Rheumatologist, Schroeder Arthritis Institute, University Health Network. His clinical research focuses on diagnosis, imaging and management of SpA and PsA.

Nigil Haroon, MD, PhD, MBA

Professor of Medicine, University of Toronto, and Head of Rheumatology at University Health Network and Sinai Health. His work focuses on axial spondyloarthritis, disease mechanisms and treatment, and the relationship between spinal damage and function.

Vinod Chandran, MD, PhD

Professor of Medicine, University of Toronto, and Director of the Gladman-Krembil Psoriatic Arthritis Program at the Schroeder Arthritis Institute. His research examines PsA diagnosis, disease outcomes and treatment.

Kay-Geert Hermann, MD, PhD

Professor of Radiology and musculoskeletal radiologist at Charité – Universitätsmedizin Berlin. His research centres on imaging inflammatory arthritis, including MRI of the sacroiliac joints and spine and methods to improve image acquisition and interpretation.

Faculty disclosures

DRAFT FOR FACULTY REVIEW. Dr. Poddubnyy's entry incorporates his recent Journal of Rheumatology editorial declaration and chair support. Other entries summarize 2026 publications. Faculty should verify these against their declarations for this activity.

Denis Poddubnyy

Research grants: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB. Consulting fees: AbbVie, Eli Lilly, GlaxoSmithKline, Greywolf Therapeutics, Johnson & Johnson, Merck, MoonLake Immunotherapeutics, Novartis, Pfizer and UCB. Supported by a Krembil Foundation grant; holder of the Pfizer Canada Chair in Rheumatology at the University of Toronto. ASAS executive committee member and GRAPPA steering committee member.

Vinod Chandran

Research grants: AbbVie, Amgen and Eli Lilly. Advisory board honoraria: AbbVie, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Janssen, Novartis and UCB. His spouse is employed by AstraZeneca. Supported through the Dr. Dafna D. Gladman Chair in Psoriatic Arthritis Research.

Nigil Haroon

Consulting: AbbVie, Eli Lilly, Novartis and UCB.

Kay-Geert Hermann

Consulting: AbbVie. Lecture fees: Novartis, Pfizer and UCB. Co-founder of BerlinFlame GmbH

Accreditation

Accreditation and eligible Section 1 credits for the 2026 meeting are pending confirmation.